• Support
  • Client Login
  • Learn More
  • Solutions
    • Commercial Analytics
    • Observational Research
    • Precision & HCP Marketing
    • Real-World Evidence (RWE)
    • HEOR
  • About
    • Become a Data Provider
    • Careers
    • News
    • Resources
  • Insights
  • Contact Us
Home Insights The Value of Using Lab Data

The Value of Using Lab Data

  • January 22, 2019
  • Posted in Lab Testing Insights
The Value of Using Lab Data

By Heather Von Allmen

Arthur Conan Doyle’s ubiquitous fictional detective Sherlock Holmes once said, “It is a capital mistake to theorize before one has data.” Indeed, good data can make or break many healthcare organizations — including pharmaceutical companies. In particular, anonymized lab data can prove useful to these companies for many reasons:

  1. It can help them evaluate testing behaviors. When a pharmaceutical product is approved for use, prescribing information includes details about how the medicine is to be prescribed. In some cases, physicians need to monitor certain health indicators — for example, liver and kidney function — routinely while the patient is taking the drug, and adjust dosing or therapy appropriately. By linking diagnostic lab results with other anonymized Real World Data, companies can understand if physicians are routinely testing patients and making proper adjustments to their therapy. This information can be used to determine if additional education is needed for physicians to ensure prescribing instructions are followed consistently, improving patient care.
  2. It provides additional insights into patient outcomes. The purpose of any given medication is to improve whatever condition precipitated the prescription in the first place. When pharmaceutical companies have access to longitudinal lab results linked with other Real World Data, they can see whether patients on their product have better outcomes, as evidenced by improved test levels and/or fewer complications, resulting in lower cost of care.
  3. It can show payers that the treatment is working. Ultimately, pharmaceutical companies want patients to be able to get access to their medications. The physician’s decision to prescribe and patient’s willingness to fill the prescription is driven by many different factors, including the willingness of insurance companies to cover the cost of a given medication. If a pharmaceutical company can provide evidence, via an outcomes study that includes diagnostic test results, that their medication works better than other options on the market, that can mean patients get access to a medication that can improve their health.

Prognos can work with companies to extract the lab results they need to monitor testing and measure patient outcomes and link it to a variety of prescription and claims data sources. Additionally, through its artificial intelligence (AI) capabilities, Prognos can identify correlations in the data that humans would not be able to see, and use those correlations to help pharmaceutical companies evaluate their product’s efficacy more easily. Not only does Prognos extract the data, but it can also organize that information so that it is usable and useful. Sherlock Holmes would be proud.

« HbA1c scores influence HCPs’​ therapy choices
Reflections on the PMSA Winter Symposium »

    Categories

    • AI (7)
    • Alerts (4)
    • artificial intelligence (1)
    • Blood Cancer (1)
    • Blood Cancer Awareness Month (1)
    • Clinical (1)
    • Commercial Launch Excellence (2)
    • diabetes (1)
    • diagnosis (1)
    • digital (1)
    • Disease Awareness (14)
    • HbA1c (1)
    • HCP omnichannel marketing (1)
    • healthcare AI (1)
    • Lab Testing Insights (17)
    • Lab Testing Trends (11)
    • Marketplace (8)
    • Omnichannel Marketing (8)
    • Patient Journey (1)
    see all topics

    Archives

    • May 2022 (1)
    • April 2022 (2)
    • March 2022 (1)
    • February 2022 (2)
    • November 2021 (3)
    • October 2021 (2)
    • September 2021 (4)
    • August 2021 (1)
    • May 2021 (2)
    • March 2021 (2)
    • January 2021 (1)
    • December 2020 (1)
    • September 2020 (1)
    • August 2020 (1)
    • July 2020 (4)
    • June 2020 (4)
    • May 2020 (4)
    • March 2020 (1)
    • February 2020 (1)
    • January 2020 (1)
    • September 2019 (1)
    • August 2019 (1)
    • July 2019 (1)
    • June 2019 (2)
    • April 2019 (1)
    • March 2019 (2)
    • February 2019 (3)
    • January 2019 (2)
    • November 2018 (1)
    • June 2018 (1)
    • April 2018 (1)
    • November 2017 (3)
    • October 2017 (1)
    • June 2017 (4)
    • May 2017 (1)
    • April 2017 (1)
    see all
    • Prognos Factor®
      • Prognos Marketplace
    • Products
      • Life Sciences
    • Company
      • Insights
      • Careers
      • News
    • Contact Us
    • Terms of Use
    • Privacy Policy
    • Site Map
    © Prognos Health, 2022. All Rights Reserved.